Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer.
T Hirose, Y Murata, Y Oki, T Sugiyama… - Oncology …, 2012 - europepmc.org
The aim of this study was to investigate the relationship of the number of circulating tumor
cells (CTCs) with the effectiveness of cytotoxic chemotherapy in patients with metastatic non-…
cells (CTCs) with the effectiveness of cytotoxic chemotherapy in patients with metastatic non-…
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung …
T Hirose, K Fujita, S Kusumoto, Y Oki, Y Murata… - Lung Cancer, 2016 - Elsevier
Objectives Gefitinib is a potent epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor and is a key drug for patients with EGFR mutation-positive advanced non-small cell …
inhibitor and is a key drug for patients with EGFR mutation-positive advanced non-small cell …
Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial …
K Okuda, T Hirose, Y Oki, Y Murata… - Anticancer …, 2012 - ar.iiarjournals.org
Background: Acute chemotherapy-associated exacerbation of interstitial lung disease (ILD)
can occur in patients with non-small cell lung cancer (NSCLC). The safety and efficacy of …
can occur in patients with non-small cell lung cancer (NSCLC). The safety and efficacy of …
[HTML][HTML] Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer
…, T Hirose, J Yokouchi, Y Oki… - Molecular and …, 2014 - spandidos-publications.com
Patients with non‑small cell lung cancer (NSCLC) have locally advanced disease with poor
prognosis. Although concurrent chemoradiotherapy is the standard treatment, more effective …
prognosis. Although concurrent chemoradiotherapy is the standard treatment, more effective …
[HTML][HTML] Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer
Y Oki, T Hirose, T Yamaoka, S Kusumoto… - Cancer chemotherapy …, 2011 - Springer
Purpose We examined the safety and efficacy of the combination of S-1 and biweekly
docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). …
docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). …
Agrometeorological conditions of grassland vegetation in central Mongolia and their impact for leaf area growth
S Miyazaki, T Yasunari, T Miyamoto… - Journal of …, 2004 - Wiley Online Library
The long‐term observation of surface heat and water budget and hydrometeorological
elements has been carried out over a grassland site at Arvaikheer (46.23N, 102.82E) in central …
elements has been carried out over a grassland site at Arvaikheer (46.23N, 102.82E) in central …
Effect of age on exercise-induced bronchoconstriction in children and adolescents with asthma
…, H Matsuzaki, H Odajima, T Oki, Y Yasunari… - Journal of …, 2022 - Taylor & Francis
Objective The relationship between exercise-induced bronchoconstriction (EIB) and exertional
dyspnea in children and adolescents is yet to be fully established. This study examined …
dyspnea in children and adolescents is yet to be fully established. This study examined …
TNF transactivation of EGFR protects EGFR-TKI, gefitinib induced pulmonary epithelial cell apoptosis and injury in TNF transgenic mice
T Yamaoka, Y Oki, Y Murata, S Kusumoto, H Ishida… - Cancer Research, 2014 - AACR
Background: TNF is a cytokine with many biological properties including both anti- and pro-apoptotic
signaling pathways. However, the molecular switch, which determines TNF …
signaling pathways. However, the molecular switch, which determines TNF …
The characteristics of an acquired dual resistance to EGFR & MET inhibitors in non-small cell lung cancer, harboring active mutation of EGFR.
T Yamaoka, Y Ichihashi, Y Murata, Y Oki, T Sugiyama… - Cancer Research, 2013 - AACR
BACKGROUND. The selective inhibitors of EGFR tyrosine kinase, gefitinib and erlotinib,
prevent binding of ATP to the ATP-binding pocket in a competitive manner and then leading to …
prevent binding of ATP to the ATP-binding pocket in a competitive manner and then leading to …
Successful Treatment of Seasonal Influenza A (H3N2) infection-related Hemophagocytic Lymphocytosis in an Elderly Man
…, Y Miyata, Y Murata, Y Kishino-Oki… - … zasshi. The Journal …, 2016 - europepmc.org
A 79-year-old man experienced severe chronic obstructive pulmonary disease (COPD) and
was receiving treatment for ischemic heart disease. Starting from dizziness and chilliness, …
was receiving treatment for ischemic heart disease. Starting from dizziness and chilliness, …